Eli Lilly and Company $LLY Stock: Lighthouse Financial LLC Increases Stake

Lighthouse Financial LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 10.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,747 shares of the company’s stock after purchasing an additional 558 shares during the quarter. Eli Lilly and Company accounts for 3.0% of Lighthouse Financial LLC’s portfolio, making the stock its 8th largest position. Lighthouse Financial LLC’s holdings in Eli Lilly and Company were worth $6,650,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital Investment Advisors LLC boosted its stake in Eli Lilly and Company by 51.3% in the 3rd quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock valued at $51,896,000 after buying an additional 15,214 shares in the last quarter. Wedbush Securities Inc. grew its position in Eli Lilly and Company by 3.4% in the third quarter. Wedbush Securities Inc. now owns 19,230 shares of the company’s stock valued at $22,250,000 after acquiring an additional 627 shares during the period. Vision Financial Markets LLC raised its stake in Eli Lilly and Company by 10.5% during the third quarter. Vision Financial Markets LLC now owns 420 shares of the company’s stock worth $486,000 after acquiring an additional 40 shares in the last quarter. Atala Financial Inc raised its stake in Eli Lilly and Company by 1.9% during the third quarter. Atala Financial Inc now owns 547 shares of the company’s stock worth $633,000 after acquiring an additional 10 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its stake in Eli Lilly and Company by 3.4% during the third quarter. Fifth Third Wealth Advisors LLC now owns 25,916 shares of the company’s stock worth $29,987,000 after acquiring an additional 848 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LLY shares. Guggenheim lifted their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. Citigroup increased their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. HSBC lifted their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Finally, UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,320.25.

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A U.S. judge declined to block Eli Lilly’s advertising for its weight-loss drugs in a case brought by Novo Nordisk. The ruling supports Lilly’s ability to market its obesity treatments and represents a favorable development in the competitive GLP-1 market. US judge won’t block Eli Lilly ads for weight-loss drugs
• Positive Sentiment: New clinical data for investigational lung-cancer drug olomorasib showed durable first-line activity in KRAS G12C-mutated non-small-cell lung cancer, strengthening Lilly’s pipeline beyond its obesity and diabetes franchises. New data on Lilly’s investigational treatment olomorasib
• Positive Sentiment: Early Phase 1 results for Lilly’s investigational sofe-m plus bevacizumab regimen in ovarian cancer showed high response and disease-control rates without major new safety signals. Although preliminary, the data add potential long-term value to the oncology pipeline. Lilly reports strong Phase 1 ovarian cancer data
• Positive Sentiment: The board declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The announcement provides a modest signal of financial confidence, though the dividend is not likely to be the primary stock catalyst. Lilly declares fourth-quarter 2026 dividend
• Neutral Sentiment: Analysts have high expectations for the October 29 earnings report, with investors focused on demand for weight-loss drugs, prescription trends, manufacturing capacity and updated full-year guidance. A strong report could extend the rally, while any miss could prompt volatility. Wall Street has high expectations for Eli Lilly
• Negative Sentiment: Competition from Novo Nordisk and broader pricing, patent and market-access pressures remain risks. Analysts also caution that revenue could temporarily soften even as patient numbers grow, while Lilly’s elevated valuation leaves the stock sensitive to weaker-than-expected guidance. Why revenue could dip even as patients grow

Eli Lilly and Company Price Performance

LLY opened at $1,279.29 on Tuesday. The company’s 50 day simple moving average is $1,187.35 and its 200-day simple moving average is $1,086.38. The stock has a market capitalization of $1.20 trillion, a P/E ratio of 42.93, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46. Eli Lilly and Company has a one year low of $809.63 and a one year high of $1,321.21. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.